Evidence map›Paper›PMID 42097035›Full record

ReviewRedox biology2026

NOS2 and COX2 impact the spatial landscape of CD8

Lisa A Ridnour, Robert Ys Cheng, William F Heinz, Leandro L Coutinho, Erika M Palmieri, M Cristina Rangel, Stephen K Anderson, Daniel W McVicar, Stephen M Hewitt, Stephen Tc Wong and 7 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Redox biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Lisa A RidnourCancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.
Robert Ys ChengCancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.
William F HeinzOptical Microscopy and Analysis Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc. for the National Cancer Institute, Frederick, MD, USA.
Leandro L CoutinhoCancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA; Faculdade de Medicina da Universidade de São Paulo and Comprehensive Center for Precision Oncology, Universidade de São Paulo, São Paulo, SP, Brazil.
Erika M PalmieriCancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.
M Cristina RangelFaculdade de Medicina da Universidade de São Paulo and Comprehensive Center for Precision Oncology, Universidade de São Paulo, São Paulo, SP, Brazil.
Stephen K AndersonCancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA; Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Daniel W McVicarCancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.
Stephen M HewittLaboratory of Pathology CCR, NCI, NIH, Bethesda, MD, USA.
Stephen Tc WongHouston Methodist Neal Cancer Center, Weill Cornell Medical College, Houston Methodist Hospital, Houston, TX, USA.
Xiaoxian LiDepartment of Pathology and Laboratory Medicine, East Carolina University, Greenville, NC, USA.
Stefan AmbsLaboratory of Human Carcinogenesis, CCR, NCI, NIH, Bethesda, MD, USA.
Timothy R BilliarDepartment of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Sharon A GlynnDiscipline of Pathology, Lambe Institute for Translational Research, School of Medicine, University of Galway, Galway, Ireland.
Jenny C ChangHouston Methodist Neal Cancer Center, Weill Cornell Medical College, Houston Methodist Hospital, Houston, TX, USA.
Stephen J LockettOptical Microscopy and Analysis Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc. for the National Cancer Institute, Frederick, MD, USA.
David A WinkCancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA. Electronic address: wink@mail.nih.gov.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nitric oxide synthase 2 (NOS2) and cyclooxygenase 2 (COX2) tumor expression present significant obstacles for effective treatment of aggressive tumors including ER-negative breast cancer. Spatial analysis of NOS2, COX2 and CD8 expression in patient tumors has identified mechanisms of treatment inhibition that were further elucidated using the 4T1 mouse model of triple negative breast cancer and live cell culture studies. NOS2 and COX2 activate each other via a feed-forward paracrine mechanism. While NOS2 promotes cancer stemness and the formation of metastatic niches, COX2 mediates CD8

Indexed as

Breast NeoplasmsCD8-Positive T-LymphocytesCyclooxygenase 2Nitric Oxide Synthase Type IIAnimalsDisease ProgressionFemaleGene Expression Regulation, NeoplasticHumansMiceTumor MicroenvironmentCyclooxygenase 2Nitric Oxide Synthase Type IINOS2 protein, humanBreast cancerCOX2ImmunosuppressionNOS2Spatial

Identifiers

PMID42097035
PMCPMC13157021

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.